Javascript must be enabled to continue!
Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
View through CrossRef
BackgroundRecently, the Age–Bleeding–Organ Dysfunction (ABO) algorithm was recommended by the Asian Pacific Society of Cardiology Consensus as a binary approach to evaluate bleeding risk. This analysis made comparison of the predictive performances between the PRECISE-DAPT and ABO bleeding score in identifying the risk of 12-months major bleeding in Chinese elderly patients over 65 years old patients who underwent percutaneous coronary intervention (PCI) during dual-antiplatelet therapy period.MethodsA total of 2,037 elderly coronary artery disease (CAD) patients (≥65 years) receiving dual antiplatelet therapy (DAPT) after PCI were enrolled in the study. The predictive accuracy of the two bleeding risk scores (PRECISE-DAPT and ABO) was compared for identifying the risk of bleeding during the dual-antiplatelet therapy in patients who underwent PCI. Major clinically relevant bleeding events were defined according to the Bleeding Academic Research Consortium (BARC) criteria.ResultsThe PRECISE-DAPT score in the no bleeding, BARC = 1 bleeding, BARC ≥ 2 bleeding patients was 23.55 ± 10.46, 23.23 ± 10.03, and 33.54 ± 14.33 (p < 0.001), respectively. Meanwhile, the ABO score in the three groups was 0.72 ± 0.80, 0.69 ± 0.81, and 1.49 ± 0.99 (p < 0.001), respectively. The C-statistic of the PRECISE-DAPT model for prediction of BARC ≥ 2 bleeding in overall patients was 0.717 (95% CI, 0.656–0.777) and 0.720 (95% CI, 0.656–0.784) in acute coronary syndrome (ACS) patients. Similar discriminatory capacity was demonstrated in the ABO risk score [overall, patients, AUC: 0.712 (95% CI, 0.650–0.774); ACS patients, AUC: 0.703 (95% CI, 0.634–0.772)]. No differences were observed when the ABO model was in comparison with the PRECISE-DAPT model, regardless in overall patients (z = −0.199, p = 0.842) or ACS patients (z = −0.605, p = 0.545). The calibration for BARC ≥ 2 bleeding of the PRECISE-DAPT and ABO score were acceptable, regardless in overall patients [goodness-of-fit (GOF) Chi-square = 0.432 and 0.001, respectively; p-value = 0.806 and 0.999, respectively] or ACS patients (GOF Chi-square = 0.008 and 0.580, respectively; p-value = 0.996 and 0.748, respectively).ConclusionNo matter of clinical presentation in Asian 65-years older patients with DAPT, the PRECISE-DAPT, and ABO scores had the similar discriminative ability for 12-months BARC ≥ 2 bleeding. Considering the simplicity and reliability, the PRECISE-DAPT score might be more clinically applicable in the overall population and ACS patients in bleeding prediction.
Title: Performance of PRECISE-DAPT and Age–Bleeding–Organ Dysfunction Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy in Chinese Elderly Patients
Description:
BackgroundRecently, the Age–Bleeding–Organ Dysfunction (ABO) algorithm was recommended by the Asian Pacific Society of Cardiology Consensus as a binary approach to evaluate bleeding risk.
This analysis made comparison of the predictive performances between the PRECISE-DAPT and ABO bleeding score in identifying the risk of 12-months major bleeding in Chinese elderly patients over 65 years old patients who underwent percutaneous coronary intervention (PCI) during dual-antiplatelet therapy period.
MethodsA total of 2,037 elderly coronary artery disease (CAD) patients (≥65 years) receiving dual antiplatelet therapy (DAPT) after PCI were enrolled in the study.
The predictive accuracy of the two bleeding risk scores (PRECISE-DAPT and ABO) was compared for identifying the risk of bleeding during the dual-antiplatelet therapy in patients who underwent PCI.
Major clinically relevant bleeding events were defined according to the Bleeding Academic Research Consortium (BARC) criteria.
ResultsThe PRECISE-DAPT score in the no bleeding, BARC = 1 bleeding, BARC ≥ 2 bleeding patients was 23.
55 ± 10.
46, 23.
23 ± 10.
03, and 33.
54 ± 14.
33 (p < 0.
001), respectively.
Meanwhile, the ABO score in the three groups was 0.
72 ± 0.
80, 0.
69 ± 0.
81, and 1.
49 ± 0.
99 (p < 0.
001), respectively.
The C-statistic of the PRECISE-DAPT model for prediction of BARC ≥ 2 bleeding in overall patients was 0.
717 (95% CI, 0.
656–0.
777) and 0.
720 (95% CI, 0.
656–0.
784) in acute coronary syndrome (ACS) patients.
Similar discriminatory capacity was demonstrated in the ABO risk score [overall, patients, AUC: 0.
712 (95% CI, 0.
650–0.
774); ACS patients, AUC: 0.
703 (95% CI, 0.
634–0.
772)].
No differences were observed when the ABO model was in comparison with the PRECISE-DAPT model, regardless in overall patients (z = −0.
199, p = 0.
842) or ACS patients (z = −0.
605, p = 0.
545).
The calibration for BARC ≥ 2 bleeding of the PRECISE-DAPT and ABO score were acceptable, regardless in overall patients [goodness-of-fit (GOF) Chi-square = 0.
432 and 0.
001, respectively; p-value = 0.
806 and 0.
999, respectively] or ACS patients (GOF Chi-square = 0.
008 and 0.
580, respectively; p-value = 0.
996 and 0.
748, respectively).
ConclusionNo matter of clinical presentation in Asian 65-years older patients with DAPT, the PRECISE-DAPT, and ABO scores had the similar discriminative ability for 12-months BARC ≥ 2 bleeding.
Considering the simplicity and reliability, the PRECISE-DAPT score might be more clinically applicable in the overall population and ACS patients in bleeding prediction.
Related Results
P1558Clinical utility of the PRECISE-DAPT score in the prediction of hemorrhagic events in elderly patients with acute coronary syndrome
P1558Clinical utility of the PRECISE-DAPT score in the prediction of hemorrhagic events in elderly patients with acute coronary syndrome
Abstract
Introduction
The clinical utility and validity of the PRECISE-DAPT bleeding risk score for elderly patients with acute ...
Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents
Prolonging Dual Antiplatelet Therapy Improves Long-term Prognosis in Diabetic Patients Undergoing Complex Percutaneous Coronary Intervention with Drug-eluting Stents
Abstract
Background The optimal dual antiplatelet therapy (DAPT) duration after percutaneous coronary intervention (PCI) remains controversial, especially for patients at h...
Early dual antiplatelet therapy versus acetylsalicylic acid monotherapy after CABG: propensity score analysis addressing survival and safety outcomes
Early dual antiplatelet therapy versus acetylsalicylic acid monotherapy after CABG: propensity score analysis addressing survival and safety outcomes
Abstract
Background
There is currently conflicting evidence regarding the security profile and outcomes of dual antiplatelet the...
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
The effect of co-treatment with DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells
Abstract
To assess the effects of the combination of DAPT and oxaliplatin on the biological behavior of human ovarian cancer stem cells. In vitro cultured human ovarian can...
P677Association between bleeding after acute coronary syndrome and newly diagnosed cancers
P677Association between bleeding after acute coronary syndrome and newly diagnosed cancers
Abstract
Introduction
There is a growing body of evidence on the incidence and negative prognostic impact of post-discharge hemo...
P3843Ischemic-bleeding balance according to history of prior bleeding in patients with acute coronary syndrome during treatment with dual antiplatelet therapy
P3843Ischemic-bleeding balance according to history of prior bleeding in patients with acute coronary syndrome during treatment with dual antiplatelet therapy
Abstract
Introduction
ESC guidelines recommend short-term dual antiplatelet therapy (DAPT) in patients with high bleeding risk. ...
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
The risk for gastrointestinal bleeding from dual antiplatelet therapy (DAPT) with new antiplatelets (prasugrel/ticagrelor) compared to clopidogrel is unclear. Aim: To determine the...
Abstract 67: Effects of Single vs Dual Antiplatelet Therapy on Long Term Stroke and Death After Carotid Endarterectomy
Abstract 67: Effects of Single vs Dual Antiplatelet Therapy on Long Term Stroke and Death After Carotid Endarterectomy
Introduction:
Current evidence suggests that dual antiplatelet therapy (DAPT) reduces perioperative stroke, but increases bleeding after carotid endarterectomy (CEA). T...

